Literature DB >> 18581211

A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs.

Taher Nassar1, Alona Rom, Abraham Nyska, Simon Benita.   

Abstract

PURPOSE: To design a double-coated nanoparticulate delivery system of tacrolimus capable of overcoming the P-glycoprotein pump and CYP3A barriers without affecting their physiological activities.
MATERIALS AND METHODS: Tacrolimus loaded oil cores were first nanoencapsulated with two polymethacrylate polymers followed by the microencapsulation of these nanocapsules within hydroxypropylmethylcellulose using a spray drying technique. The Trojan effect of these double-coated nanocapsules was evaluated in Caco-2 monolayer by monitoring the tacrolimus uptake and measuring the transport of tacrolimus across the rat jejunum membrane.
RESULTS: The formulation was shown to release nanocapsules rather than dissolved drug under sink conditions. The nanocapsules protected tacrolimus from degradation in the diluted intestinal fluids following 2 h incubation. The Caco-2 and intestinal segment uptake of tacrolimus from the novel delivery system with and without verapamil was significantly higher than the uptake of tacrolimus from the aqueous solution and emulsion. The blank drug delivery system did not inhibit the P-gp pump activity. The nanocapsules internalized rapidly in the enterocytes as confirmed by the histological results.
CONCLUSION: The overall results suggest that the novel nanodelivery system which does not alter the activity of the P-gp is a potential platform for intestinal transport of sensitive lipophilic molecules that are P-gp substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18581211     DOI: 10.1007/s11095-008-9585-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  27 in total

1.  Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity.

Authors:  B Kaplan; K Lown; R Craig; M Abecassis; D Kaufman; J Leventhal; F Stuart; H U Meier-Kriesche; J Fryer
Journal:  Transplantation       Date:  1999-01-27       Impact factor: 4.939

Review 2.  A review of low-dose ritonavir in protease inhibitor combination therapy.

Authors:  C L Cooper; R P G van Heeswijk; K Gallicano; D W Cameron
Journal:  Clin Infect Dis       Date:  2003-06-05       Impact factor: 9.079

3.  Positively charged self-emulsifying oil formulation for improving oral bioavailability of progesterone.

Authors:  T Gershanik; S Benita
Journal:  Pharm Dev Technol       Date:  1996-07       Impact factor: 3.133

4.  P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model.

Authors:  J Schrickx; J Fink-Gremmels
Journal:  J Vet Pharmacol Ther       Date:  2007-02       Impact factor: 1.786

5.  The advantages of the Ussing chamber in drug absorption studies.

Authors:  Yasumasa Gotoh; Noboru Kamada; Denichi Momose
Journal:  J Biomol Screen       Date:  2005-08

6.  Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor.

Authors:  D J Hauss; S E Fogal; J V Ficorilli; C A Price; T Roy; A A Jayaraj; J J Keirns
Journal:  J Pharm Sci       Date:  1998-02       Impact factor: 3.534

7.  Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy.

Authors:  Tsutomu Shimada; Ai Terada; Koichi Yokogawa; Hiroko Kaneko; Masaaki Nomura; Kyosuke Kaji; Shuichi Kaneko; Ken-Ichi Kobayashi; Ken-Ichi Miyamoto
Journal:  Transplantation       Date:  2002-11-27       Impact factor: 4.939

Review 8.  The implications of P-glycoprotein in HIV: friend or foe?

Authors:  Andrew Owen; Becky Chandler; David J Back
Journal:  Fundam Clin Pharmacol       Date:  2005-06       Impact factor: 2.748

9.  In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan.

Authors:  Florian Föger; Thierry Schmitz; Andreas Bernkop-Schnürch
Journal:  Biomaterials       Date:  2006-04-17       Impact factor: 12.479

10.  Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.

Authors:  Tetsuo Yamagata; Hiroyuki Kusuhara; Mariko Morishita; Kozo Takayama; Hassan Benameur; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2007-04-19       Impact factor: 3.922

View more
  5 in total

1.  Directed self-assembled nanoparticles of probucol improve oral delivery: fabrication, performance and correlation.

Authors:  Zhiwen Zhang; Shijun Jiang; Zeying Liu; Baohua Niu; Wangwen Gu; Yaping Li; Jingbin Cui
Journal:  Pharm Res       Date:  2014-03-04       Impact factor: 4.200

2.  Engineering of Long-Term Stable Transparent Nanoemulsion Using High-Gravity Rotating Packed Bed for Oral Drug Delivery.

Authors:  Hao-Ran Wu; Chuan-Qi Wang; Jie-Xin Wang; Jian-Feng Chen; Yuan Le
Journal:  Int J Nanomedicine       Date:  2020-04-09

3.  Development and Characterization of a Tacrolimus/Hydroxypropyl-β-Cyclodextrin Eye Drop.

Authors:  Xurxo García-Otero; Victoria Díaz-Tomé; Rubén Varela-Fernández; Manuel Martín-Pastor; Miguel González-Barcia; José Blanco-Méndez; Cristina Mondelo-García; Maria A Bermudez; Francisco Gonzalez; Pablo Aguiar; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2021-01-23       Impact factor: 6.321

4.  Formulation strategies for drug delivery of tacrolimus: An overview.

Authors:  Pranav Patel; Hitesh Patel; Shital Panchal; Tejal Mehta
Journal:  Int J Pharm Investig       Date:  2012-10

5.  Orally Disintegrating Tablets Containing Melt Extruded Amorphous Solid Dispersion of Tacrolimus for Dissolution Enhancement.

Authors:  Poovizhi Ponnammal; Parijat Kanaujia; Yin Yani; Wai Kiong Ng; Reginald B H Tan
Journal:  Pharmaceutics       Date:  2018-03-16       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.